However, both ACPP and PSA fall short in their diagnostic ability for prostate cancer, particularly in the lower reference ranges (2-10ng/mL) where PSA is neither able to distinguish benign from cancerous prostate disease [12] nor distinguish indolent from aggressive phenotypes of the disease [13, 14]. This evidence concerns the gene KLK3 and cancer.